Last reviewed · How we verify
NCT05601466
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Phase 1 trial testing QN-023a in AML, Adult in 3 participants. Terminated before completion.
11 April 2023
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 26 March 2022 |
| Primary completion | 11 April 2023 |
| Estimated completion | 11 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- QN-023a — full drug profile →
- Cyclophosphamid — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Cytarabine — full drug profile →
Conditions studied
- AML, Adult — all drugs for AML, Adult →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with AML, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w -
The clinical landscape of CAR NK cells.
Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8 -
NK cell defects: implication in acute myeloid leukemia.
D'Silva SZ, Singh M, Pinto AS. · · 2023 · cited 24× · PMID 37228595 · DOI 10.3389/fimmu.2023.1112059 -
Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
Kent A, Crump LS, Davila E. · · 2023 · cited 21× · PMID 37654497 · DOI 10.3389/fimmu.2023.1202950 -
NK cells as powerful therapeutic tool in cancer immunotherapy.
Huang M, Liu Y, Yan Q, Peng M, et al · · 2024 · cited 10× · PMID 38170381 · DOI 10.1007/s13402-023-00909-3 -
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
Andrea AE, Chiron A, Sarrabayrouse G, Bessoles S, et al · · 2024 · cited 8× · PMID 39430751 · DOI 10.3389/fimmu.2024.1459818 -
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
Wang Y, Jin S, Zhuang Q, Liu N, et al · · 2023 · cited 8× · PMID 38045827 · DOI 10.1002/mco2.422 -
CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.
Zhang L, Meng Y, Yao H, Zhan R, et al · · 2023 · cited 7× · PMID 38058830
Verify or expand the search:
- PubMed search for NCT05601466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of QN-023a
Trials testing the same drug.
- NCT05665075 — Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia · Phase 1 · unknown
Other recruiting trials for AML, Adult
Currently open trials in the same condition.
- NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
- NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
- NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
- NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
- NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05601466 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 6 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing